Stryker Corporation $SYK Shares Sold by Hollencrest Capital Management

Hollencrest Capital Management lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 99.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 199 shares of the medical technology company’s stock after selling 25,239 shares during the period. Hollencrest Capital Management’s holdings in Stryker were worth $63,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new stake in Stryker during the 2nd quarter worth about $25,000. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the 4th quarter valued at about $26,000. Sankala Group LLC purchased a new stake in Stryker during the 4th quarter valued at about $26,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker in the second quarter valued at about $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 2.9%

Shares of SYK opened at $331.32 on Friday. The company has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The stock’s 50-day moving average price is $329.10 and its 200-day moving average price is $331.47. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the business earned $3.13 earnings per share. Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Insider Activity at Stryker

In related news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 in the last three months. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Leerink Partners cut their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. BTIG Research dropped their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Finally, UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.